Back to search
FDAFDA · Food and drugs·Recall number D-0006-2016

Sermorelin 6mg/6mL Lyophilized Powder, Sterile Compound for Subcutaneous Injection, Diabetes Corporation of America dba DCA Pharmacy, Franklin, TN 37064-5527

Published October 14, 2015 · Recall initiated: September 23, 2015

Summary

FDA records drug Class II recall D-0006-2016, published October 14, 2015 and initiated September 23, 2015. Recalling firm: Diabetes Corporation of America dba DCA Pharmacy; Status: Terminated; Reported quantity: 129 vials; Lot: Lot #: 101614, Exp 4/30/2015. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: A recent FDA inspection found that this product was not being compounded in an area appropriate for lyophilization which may lead to a lack of sterility assurance.

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Diabetes Corporation of America dba DCA Pharmacy
Distributor
KY, OH, TN
Lot
Lot #: 101614, Exp 4/30/2015
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Sermorelin 6mg/6mL Lyophilized Powder, Sterile Compound for Subcutaneous Injection, Diabetes Corporation of America dba DCA Pharmacy, Franklin, TN 37064-5527 recalled?

Yes. FDA published recall D-0006-2016 on October 14, 2015. Reported hazard: Lack of Assurance of Sterility: A recent FDA inspection found that this product was not being compounded in an area appropriate for lyophilization which may lead to a lack of sterility assurance.

What should I do if I have this product?

Voluntary: Firm initiated · Telephone